Skip to main content

Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives.

Kim SY, Kim TE, Park CK, Yoon HK, Sa YJ, Kim HR, Woo IS, Kim TJ

Publication: Cancers (Basel) (2022) • Vol 14PMID: 35804910View on PubMed

Purpose

This paper evaluated the concordance of the tumor proportion score (TPS) for PD-L1 positive immunohistochemical staining using two different assays (22C3 or SP263 antibodies) among non-small-cell lung cancer (NSCL) specimens procured by different methods and specimens stored for < 1 y and in archival specimens stored as FFPE blocks for longer than 6 y. The stability of PD-L1 antigenicity in stored FFPE sections from archival blocks was also assessed in slides that were analyzed immediately after sectioning and those that were stored at room temperature or 4°C for 1 week to 1 month.

Conclusion

While concordance between the two PD-L1 assays was generally high (89.9-100%), an effect of tissue acquisition method and primary versus metastatic sampling location was observed.  The concordance between PD-L1 assays was higher among surgically resected NSCLC specimens (90.2-100%) compared to biopsy (69.2-81.9%) and cytology (66.7%) specimens, and among lung specimens (R2= 0.85) compared to those sampled from a metastatic site (R2=0.68). Concordance between PD-L1 assays was also significantly higher among FFPE blocks stored for less than 6 months compared to those stored for 6-12 months before analysis (p=0.003). 

The distribution of specimens classified as PD-L1 negative, having low PD-L1 expression, or high PD-L1 expression differed among the FFPE block storage durations examined regardless of the assay. Specimens stored as FFPE blocks for less than 3 years had a similar number of specimens in each PD-L1 expression category, while FFPE blocks stored for ≥3 years had a significantly greater number of specimens that were PD-L1 negative than those with low or high expression, suggesting that FFPE block storage for 3 years or longer may increase the prevalence of false negatives.

The duration and temperature of FFPE slide storage prior to analysis affected PD-L1 expression in an antibody-specific manner. The authors conclude that when assessed with the SP263 antibody, PD-L1 expression was preserved in slides stored for up to 1 month at either room temperature or 4°C.  Conversely, significant differences in PD-L1 staining assessed with the 22C3 antibody occurred after 1 week of FFPE slide storage at room temperature. Linear regression analysis revealed that the strength of the correlation between PD-L1 assays (22C3 and SP263) decreased with the duration of FFPE slide storage when storage was at room temperature (R2= 0.86-0.73) but not 4°C (R2=0.85-0.86).

Studies (2)

Purpose

This study compared PD-L1 immunohistochemical staining results from two different assays using NSCLC specimens that were procured by different methods and were stored as FFPE blocks for <6 months or 6-12 months prior to analysis. A total of 431 NSCLC specimens were analyzed, which included adenocarcinoma (282 specimens), squamous cell carcinoma (133 specimens), adenosquamous carcinoma (7 specimens), and large cell neuroendocrine carcinoma and sarcomatoid carcinoma specimens (9 specimens total).  NSCLC specimens included those that were collected by bronchoscopy biopsy (83 specimens), percutaneous needle aspiration biopsy (PCNB, 256 specimens), biopsy of a metastatic site (26 specimens), endobronchial ultrasound biopsy (EBUS, 15 specimens), an unspecified cell aspiration method (6 specimens), and surgical resections that included both lobectomy (41 specimens) and wedge resection (4 specimens). Specimens were fixed in 10% buffered formalin immediately (biopsies) or after receipt in the pathology department (surgical resections) and stored as FFPE blocks for <6 months or 6-12 months.  Additional details of tissue fixation, processing, and storage were not provided. Case-matched FFPE sections (4 µm thick) were stained for PD-L1 immunostaining with the PD-L1 22C3 pharmDx Kit and the SP263 assay; slides were semi-quantitatively scored for tumor proportion score (TPS; the number of immunopositive tumor cells divided by the number of viable tumor cells) by two pathologists. Any perceptible staining in the membrane of viable tumor cells was considered positive.  The authors defined three categories based on perceived clinical relevance of PD-L1 results: negative (1% TPS), low expression (1-49% TPS), high expression (≥50% TPS).

Summary of Findings

When all FFPE NSCLC specimens were considered (regardless of method of acquisition or FFPE storage duration), overall concordance between the 22C3 and SP263 PD-L1 immunohistochemistry assays was high when results were classified as positive (TPS≥1%) or negative (0%) (89.9-92.3%), as well as across TPS categories of protein expression (high expression: 79.6-100.0%; low expression: 89.9-100.0%). However, concordance between the two PD-L1 assays was significantly lower in cytology (66.7%) and biopsy (metastatic site biopsy= 69.2%, EBUS=80.0%, PCNB=81.3%, bronchoscopy biopsy=81.9%) specimens than surgically resected specimens (wedge resection=100%, lobectomy= 90.2%)(p<0.001). Concordance between PD-L1 assays was also significantly higher among FFPE blocks stored for less than 6 months compared to those stored for 6-12 months before analysis (p=0.003).  Concordance between PD-L1 assays was lower in biopsy specimens collected from a metastatic site than those sampled from lung (R2=0.68 versus 0.85, respectively).

  • Biospecimens

    TissueLung
  • Preservation Types

    Formalin
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    ProteinImmunohistochemistry
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen AcquisitionBiospecimen location
    Metastatic site
    Primary tumor
    Biospecimen AcquisitionMethod of tissue acquisition
    Endoscopic biopsy
    Fine needle aspiration
    Lobectomy
    Partial surgical resection
    Ultrasound-guided biopsy
    StorageStorage duration
    <6 months
    ≥6 months
    Immunohistochemistry SpecificType of antibody
    22C3
    SP263